In collaboration with the Vaccine Research Center/National Institute of Allergy and Infectious Diseases/National Institutes of Health, GenVec is developing a vaccine candidate to protect against the three most common types of HIV-1 virus found around the world, clades A, B and C.  The vaccine candidate utilizes GenVec’s proprietary adenovector delivery technology and 293-ORF6 production cell line and is designed to generate a broad spectrum of immune responses including neutralizing antibodies and cytolytic T cell immunity characteristic of the most effective vaccines.

The Vaccine Research Center is managing the clinical development of this program.  The vaccine candidate (VRC-HIVADV014-00VP) is being evaluated  alone and in combination with a plasmid DNA vaccine prime.  In October 2005, the VRC announced the initiation of Phase II testing for this vaccine candidate.  In addition, six Phase I trials have completed enrollment with more than 150 healthy participants having received the adenovector vaccine candidate.

In 2004, GenVec announced an expanded collaboration to include the development of a second-generation vaccine candidate. This program is being funded through a subcontract managed and administered by SAIC-Frederick, Inc. worth up to $50 million.